Robert Busch, MD

1:27 Diabetes, kidney disease, and CV risk interrelationship

3:54 Expanding indications for SGLT2 inhibitors for CV risk reduction

5:40 CV benefits of SGLT2 inhibitors in clinical trials

9:20 Using stage and severity of CKD to guide treatment choice

14:00 Benefits of combining finerenone with SGLT2 inhibitors

16:30 Potential use of GLP 1 agonists for CKD

19:20 Considerations for incorporating therapies for CKD

23:00 Key takeaways on using new treatments for CKD

Videos

Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.

Protecting Cardiorenal Function In Diabetic Kidney Disease

To watch the video series component of this episode, click here.

Podcasts

Experts discuss the intricate relationship between diabetes, kidney disease, and cardiovascular function and explore the evolving landscape of therapies with cardiorenal benefits.

Protecting Cardiorenal Function in Diabetic Kidney Disease

3:28 Topline findings for semaglutide in the SELECT trial

8:54 Perspectives on cost-benefit for GLP-1 in obesity

16:44 Considerations for using GLP-1 agonists

20:54 Need to address inequity in access to obesity medications

26:44 Investigational therapies for obesity with potential for CV benefits

30:00 Combination therapy for obesity and CV risk

Robert Busch, MD

Articles